The Full Wiki

More info on Besifloxacin

Besifloxacin: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
7-[(3R) -3-aminoazepam- 1-yl]- 8-chloro- 1-cyclopropyl- 6-fluoro- 4-oxo- 1,4- dihydroquinoline- 3-carboxylic acid
CAS number 141388-76-3
ATC code none
PubChem  ?
Chemical data
Formula C 19H21ClFN3O3  
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes Opthalmic

Besifloxacin (INN/USAN) is a fourth-generation fluoroquinolone antibiotic. The marketed compound is besifloxacin hydrochloride. It was developed by SSP Co. Ltd., Japan, and designated SS734. SSP licensed U.S. and European rights to SS734 for ophthalmic use to InSite Vision, Inc., in 2000. InSite Vision developed an eye drop formulation (ISV-403) and conducted preliminary clinical trials before selling the product and all rights to Bausch & Lomb in 2003.[1]

The eye drop was approved by the United States Food and Drug Administration (FDA) on May 29, 2009 and marketed under the trade name Besivance.[2]

Besifloxacin has been found to inhibit production of pro-inflammatory cytokines in vitro.[3]

See also


  1. ^ InSite Vision (2003-12-19). "InSite Vision Reaches Agreement to Sell ISV-403 to Bausch & Lomb". Press release. Retrieved 2009-08-15.  
  2. ^ Bausch & Lomb (2009-05-29). "Bausch & Lomb Receives FDA Approval of Besivance, New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis (“Pink Eye”)". Press release. Retrieved 2009-05-29.  
  3. ^ Zhang JZ, Ward KW (January 2008). "Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes". J. Antimicrob. Chemother. 61 (1): 111–6. doi:10.1093/jac/dkm398. PMID 17965029.  


Got something to say? Make a comment.
Your name
Your email address